What Should Investors Watch With AbbVie?

In the video below, Fool health care bureau chief Brenton Flynn talks about AbbVie with a focus on a few areas that investors should watch over the near term.

The first is Humira, which made up half of sales in 2012 and delivered an even higher percentage of profits. It will continue to be a key element of AbbVie's revenue growth. International growth is also worth keeping an eye on, as is AbbVie's pipeline. Humira is expected to face challenges as it loses patent protection in 2016, so knowing what new drugs the company will be selling is a very important development.

If you want more details on AbbVie, The Fool's brand new premium report on the company answers the high-profile questions that AbbVie investors are asking. Simply click here now to claim your copy today.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2343792, ~/Articles/ArticleHandler.aspx, 7/23/2014 7:02:23 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement